Intelligent Bio Solutions, Inc. operates as a biosensor diagnostic technology company. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

The full company name is Gui Bin She International Holding Group.

- Name change to more closely reflect firm's expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products -

GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) --  GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

GBS, Inc. (NASDAQ:GBS ) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode.

GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition -

GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health's Mills-Peninsula Medical Center (MPMC) in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types.

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology.

GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care (the “Company”), today announced that the Company has adjourned its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 16, 2022, to July 13, 2022, at 4:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned.

GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022

- Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline - Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:

GBS Inc. to Present at the H.C. Wainwright Global Investment Conference

GBS Inc. (NASDAQ:GBS ) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call.

GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, GBS's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The Company's proxy statement describing the formal business to be conducted at the meeting is available on the Investors section of the Company's website at: https://www.cstproxy.com/gbs/2022 Please see additional details below:

GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval -

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10

The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center

Clarus Therapeutics Holdings

Denison Mines

Gevo

Are these trending penny stocks on your watchlist right now? The post 4 Trending Penny Stocks to Add to Your Watchlist Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Trending Penny Stocks to Add to Your Watchlist Right Now

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in March and invites investors to participate in one-on-one meetings. Please see additional details below:

GBS Inc. to Participate in the Upcoming March Investor Conferences

GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government -

GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:

GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that in collaboration with Life Science Biosensor Diagnostics Pty Ltd (LSBD), the licensor of the Rapid Saliva Glucose Test [that forms part of the Biosensor Platform licensed by GBS Inc. (GBS)], LSBD has filed an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation.

GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

The stock price of GBS Inc (NASDAQ: GBS) increased by over 19% during intraday trading. This is why it happened.

GBS (GBS) Stock: Why The Price Jumped Today

Shares of GBS stock are trading higher after a clinical study at Harvard University yielded positive results for the company's antibody test. The post GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today appeared first on InvestorPlace.

GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today

GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously referenced, a clinical validation study was conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University.

News for GBS Stock (GBS)